Evidence map›Paper›PMID 38502821›Full record

ArticleMutagenesis2024

Adapting the in vitro micronucleus assay (OECD Test Guideline No. 487) for testing of manufactured nanomaterials: recommendations for best practices.

Michael J Burgum, Clarissa Ulrich, Natascha Partosa, Stephen J Evans, Caroline Gomes, Svenja Berit Seiffert, Robert Landsiedel, Naveed Honarvar, Shareen H Doak

Abstract read
In one paragraph

Article in Mutagenesis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. In Vitro Cytogenetic Assays: Chromosomal Aberrations and Micronucleus Tests.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  6. 3D Liver Models for Genotoxicity Testing.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Nanotoxicology: developments and new insights.Nanomedicine (London, England) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael J BurgumIn Vitro Toxicology Group, Faculty of Medicine, Health and Life Sciences, Institute of Life Sciences, Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, Wales, United Kingdom.
Clarissa UlrichBASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany.
Natascha PartosaBASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany.
Stephen J EvansIn Vitro Toxicology Group, Faculty of Medicine, Health and Life Sciences, Institute of Life Sciences, Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, Wales, United Kingdom.
Caroline GomesBASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany.
Svenja Berit SeiffertBASF SE, Analytical and Material Science, 67056, Ludwigshafen, Germany.
Robert LandsiedelBASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany.
Naveed HonarvarBASF SE, Experimental Toxicology and Ecology, 67056, Ludwigshafen, Germany.
Shareen H DoakIn Vitro Toxicology Group, Faculty of Medicine, Health and Life Sciences, Institute of Life Sciences, Swansea University Medical School, Singleton Park, Swansea, SA2 8PP, Wales, United Kingdom.ORCID 0000-0002-6753-1987

Funding

Celtic Advanced Life Science Innovation Network 2014-2020European Regional Development FundWelsh Government 80885
6 · The paper itself

Abstract

The current Organisation for Economic Co-Operation and Development test guideline number 487 (OECD TG No. 487) provides instruction on how to conduct the in vitro micronucleus assay. This assay is one of the gold standard approaches for measuring the mutagenicity of test items; however, it is directed at testing low molecular weight molecules and may not be appropriate for particulate materials (e.g. engineered nanoparticles [ENPs]). This study aimed to adapt the in vitro micronucleus assay for ENP testing and underpins the development of an OECD guidance document. A harmonized, nano-specific protocol was generated and evaluated by two independent laboratories. Cell lines utilized were human lymphoblastoid (TK6) cells, human liver hepatocytes (HepG2) cells, Chinese hamster lung fibroblast (V79) cells, whole blood, and buffy coat cells from healthy human volunteers. These cells were exposed to reference ENPs from the Joint Research Council (JRC): SiO2 (RLS-0102), Au5nm and Au30nm (RLS-03, RLS-010), CeO2 (NM212), and BaSO4 (NM220). Tungsten carbide-cobalt (WC/Co) was used as a trial particulate positive control. The chemical controls were positive in all cell cultures, but WC/Co was only positive in TK6 and buffy coat cells. In TK6 cells, mutagenicity was observed for SiO2- and both Au types. In HepG2 cells, Au5nm and SiO2 showed sub-two-fold increases in micronuclei. In V79 cells, whole blood, and buffy coat cells, no genotoxicity was detected with the test materials. The data confirmed that ENPs could be tested with the harmonized protocol, additionally, concordant data were observed across the two laboratories with V79 cells. WC/Co may be a suitable particulate positive control in the in vitro micronucleus assay when using TK6 and buffy coat cells. Detailed recommendations are therefore provided to adapt OECD TG No. 487 for testing ENP.

Indexed as

Micronucleus TestsAnimalsCell LineCricetinaeCricetulusGuidelines as TopicHep G2 CellsHumansNanostructuresOrganisation for Economic Co-Operation and DevelopmentmicronucleusNanoparticlesOECDWC/Co

Identifiers

PMID38502821
PMCPMC11040148

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.